4-氯-n-苯基吡啶甲酰胺 | 133928-61-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-n-苯基吡啶甲酰胺
• 英文名称: 4-chloro-N-phenylpicolinamide
• 英文别名: 4-chloro-N-phenylpyridine-2-carboxamide
• CAS: 133928-61-7
• 化学式: C₁₂H₉ClN₂O
• mdl: MFCD08523032
• 分子量: 232.669
• InChiKey: OXCAWSPZTRRBLP-UHFFFAOYSA-N

物化性质

• 沸点：
  301.9±27.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• WGK Germany：
  3

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-Chloro-N-Phenylpicolinamide
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Eye irritation (Category 2), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22, R36
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H319 Causes serious eye irritation.
Precautionary statement(s)
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 232,67 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-Chloro-N-Phenylpicolinamide
Acute Tox. 4; Eye Irrit. 2; <= 100 %
H302, H319
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-Chloro-N-Phenylpicolinamide
Xn, R22 - R36 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
Eye Irrit. Eye irritation
H302 Harmful if swallowed.
H319 Causes serious eye irritation.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
R36 Irritating to eyes.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  4-氯-n-苯基吡啶甲酰胺 在 碘 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以88%的产率得到4-chloro-3-iodopicolinanilide
  参考文献：
  名称：

  Nora De Souza, Marcus V.; Dodd, Robert H., Heterocycles, 1998, vol. 47, # 2, p. 811 - 827

  摘要：

  DOI：
• 作为产物：
  描述：

  4-硝基吡啶-2-甲酸 1-氧化物 在 盐酸 、 三乙胺 、 三氯化磷 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 5.5h， 生成 4-氯-n-苯基吡啶甲酰胺
  参考文献：
  名称：

  有机锂及相关试剂在合成中的应用。第9部分。4-氯吡啶吡啶-和2-氯异烟锡酰苯胺的合成和金属化。制备2,3,4-三取代吡啶的有用方法

  摘要：

  描述了4-氯吡啶啉-和2-氯异烟碱金属苯胺（）和（）的合成和金属化（nBuLi），是将吡啶甲酸和异烟酸酸进行区域特异性转化为2,3,4-三取代的吡啶（）和（）的方法。形成的C 3取代的氯代苯胺（）和（）的苯胺部分（掩蔽基团）在酸水解时似乎可以有效去除。

  DOI：

  10.1016/s0040-4020(01)96912-1

文献信息

• [EN] POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES<br/>[FR] DÉRIVÉS D'URÉE POLYAROMATIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES MUSCULAIRES
  申请人：ANAGENESIS BIOTECHNOLOGIES S A S

  公开号：WO2021013712A1

  公开（公告）日：2021-01-28

  The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

  当前的发明提供尿素衍生物，特别是具有核心结构杂环基-NH-CO-NH-芳基-O-杂环基的化合物，用于治疗、改善、延缓、治愈和/或预防与肌肉细胞和/或卫星细胞相关的疾病或症状，如杜兴氏肌肉萎缩症、贝克氏肌肉萎缩症、虚弱或肌肉萎缩症。
• Experimental and mechanistic insights into copper(<scp>ii</scp>)–dioxygen catalyzed oxidative N-dealkylation of N-(2-pyridylmethyl)phenylamine and its derivatives
  作者：Yang Wang、Haixiong Liu、Xiaofeng Zhang、Zilong Zhang、Deguang Huang

  DOI：10.1039/c7ob02192e

  日期：——

  supported Cu(II)/O2 catalytic system was explored with the synthesis of pyridylmethyl-based compounds of carboxylate (PyCOOH), amide (PyC(O)NHPh), and imine (PyCHNPh) from the oxidative N-dealkylation of N-(2-pyridylmethyl)phenylamine (PyCH2NHPh) and its derivatives, by means of controlling the addition of a base and/or water to the reaction system under a dioxygen atmosphere at room temperature. Experimental

  探索了一种二（2-吡啶基甲基）苯胺（（PyCH 2）2 NPh）负载的Cu（II）/ O 2催化体系，并合成了基于吡啶基甲基的羧酸盐（PyCOOH），酰胺（PyC（O）NHPh ），和亚胺（PyCH NPH）从氧化ñ的-dealkylation ñ - （2-吡啶基甲基）苯胺（PyCH 2通过在室温下在双氧气氛下控制向反应体系中碱和/或水的添加来控制NHPh）及其衍生物。实验研究表明，亚胺和酰胺类可能以羧酸盐的最终氧化态相继成为前体。提出了一种循环催化机制，包括2-吡啶基甲基基团（PyCH 2-）的碱基触发的C–H键活化和从配位的亚胺底物（PyCH NPh）提取分子间的Cu– OOHα-氢原子。
• Synthesis and evaluation of new thiourea derivatives as antitumor and antiangiogenic agents
  作者：Wenjing Bai、Jianxin Ji、Qiang Huang、Wei Wei

  DOI：10.1016/j.tetlet.2020.152366

  日期：2020.10

  A series of novel thiourea derivatives were synthesized and evaluated by biological activities. Among them, compound 10e containing 3,5-bis(trifluoromethyl)phenyl moiety (R1) at the terminal thiourea and phenylamino (R2) at the terminal acyl position showed the best cytotoxic activities against seven cancer cell lines (NCI-H460, Colo-205, HCT116, MDA-MB-231, MCF-7, HepG2, PLC/PRF/5) and HUVECs. Moreover

  合成了一系列新型硫脲衍生物，并通过生物学活性对其进行了评估。其中，在末端硫脲处含有3,5-双（三氟甲基）苯基部分（R 1）在酰基末端具有苯氨基（R 2）的化合物10e对7种癌细胞系（NCI-H460， Colo-205，HCT116，MDA-MB-231，MCF-7，HepG2，PLC / PRF / 5）和HUVEC。此外，化合物10e适度抑制各种RTK，例如VEGFR2，VEGFR3和PDGFRβ。值得注意的是，在相同浓度下，10e对肿瘤形成和抗血管生成活性的抑制作用比索拉非尼和Regorafenib好得多。进一步的对接研究表明10e 可以作为癌症治疗的潜在候选人。
• Discovery of novel picolinamide-based derivatives as novel VEGFR-2 kinase inhibitors: synthesis,<i>in vitro</i>biological evaluation and molecular docking
  作者：Wuji Sun、Shubiao Fang、Hong Yan

  DOI：10.1039/c8md00057c

  日期：——

  Vascular endothelial growth factor receptor-2 (VEGFR-2) plays a crucial role in tumor angiogenesis, and inhibition of the VEGFR-2 signaling pathway has emerged as an attractive target for cancer therapy. In our effort, a novel series of picolinamide-based derivatives were designed and synthesized as potent and effective VEGFR-2 inhibitors. All the newly prepared compounds were evaluated in vitro for

  血管内皮生长因子受体2（VEGFR-2）在肿瘤血管生成中起着至关重要的作用，而对VEGFR-2信号通路的抑制已成为癌症治疗的诱人靶标。在我们的努力中，设计并合成了一系列新的基于吡啶啉酰胺的衍生物，它们是有效且有效的VEGFR-2抑制剂。在体外评估所有新制备的化合物对A549和HepG2细胞系的抗增殖活性。在新化合物中，8j和8l对A549和HepG2细胞系均表现出更好的活性。进行分子对接以研究与VEGFR-2（PDB代码：4ASD）的结合能力和结合方式。
• Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure–Activity Relationship and Target Identification Studies
  作者：Colin R. Wilson、Richard K. Gessner、Atica Moosa、Ronnett Seldon、Digby F. Warner、Valerie Mizrahi、Candice Soares de Melo、Sandile B. Simelane、Aloysius Nchinda、Efrem Abay、Dale Taylor、Mathew Njoroge、Christel Brunschwig、Nina Lawrence、Helena I. M. Boshoff、Clifton E. Barry、Frederick A. Sirgel、Paul van Helden、C. John Harris、Richard Gordon、Sonja Ghidelli-Disse、Hannah Pflaumer、Markus Boesche、Gerard Drewes、Olalla Sanz、Gracia Santos、Maria José Rebollo-Lopez、Beatriz Urones、Carolyn Selenski、Maria Jose Lafuente-Monasterio、Matthew Axtman、Joël Lelièvre、Lluis Ballell、Rudolf Mueller、Leslie J. Street、Sandeep R. Ghorpade、Kelly Chibale

  DOI：10.1021/acs.jmedchem.7b01347

  日期：2017.12.28

  homeostasis, and DNA damage. Among the hits that passed this screening cascade, a 6-dialkylaminopyrimidine carboxamide series was prioritized for hit to lead optimization. Compounds from this series were active against clinical Mtb strains, while no cross-resistance to conventional antituberculosis drugs was observed. This suggested a novel mechanism of action, which was confirmed by chemoproteomic analysis

  针对结核分枝杆菌（Mtb），筛选了约3.5万种化合物的BioFocus DPI SoftFocus库，以鉴定具有抗结核活性的新型命中物。在生物学分类试验中评估了这些命中物，以排除建议通过经常遇到的混杂作用机制起作用的化合物，包括抑制细胞色素bc 1的QcrB亚基。复杂，细胞壁稳态破坏和DNA损伤。在通过该筛选级联反应的命中方法中，优先选择6-二烷基氨基嘧啶羧酰胺系列以进行命中优化。该系列化合物对临床Mtb菌株具有活性，而未观察到对常规抗结核药物的交叉耐药性。这表明了一种新的作用机理，通过化学计量学分析得到了证实，从而将BCG_3193和BCG_3827鉴定为功能未知的系列的推定靶标。初步的结构活性关系研究得出了具有中等至有效抗结核活性并改善了理化性质的化合物。